Quantcast

DrugRisk Announces Yaz Settlements Leading to Drop in Lawsuits

May 24, 2013

The DrugRisk Center is the web´s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com.

Chicago, IL (PRWEB) May 24, 2013

The birth control information center at DrugRisk.com is announcing new information on the site for women who have taken the contraceptives Yaz or Yasmin. Records show the number of pending cases filed alleging blood clots has decreased as Bayer continues to settle claims*.

The goal of DrugRisk is to improve the safety of patients taking popular prescription drugs like Yaz and Yasmin, by providing the latest research, safety alerts, recalls and litigation news. Visitors can determine if others have experienced similar side effects and decide if they need legal advice.

The resource center has added warnings from health experts like the British Medical Journal** and FDA*** that birth control pills containing the hormone drospirenone, such as Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.

When thousands of patients came forward to file a Yaz lawsuit alleging blood clots, cases were consolidated to a special federal Multi-District Litigation court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)).

DrugRisk has gathered information from Bayer´s latest annual report, showing the company faced claims from as many as 13,000 patients alleging blood clot injuries like deep vein thrombosis (DVT) or pulmonary embolism****. However, the company has spent almost $1 billion so far to settle around 4,800 Yaz lawsuits, and will continue to evaluate new cases for settlement****.

Now, the resource center has learned that the latest court update from the Judicial Panel on Multidistrict Litigation shows the number of filed claims has fallen to 9,961 from the 13,000 indicated by Bayer*.

Lawyers are still helping those who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin. Anyone affected is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

Due to the specialized nature of federal MDL drug injury litigation, DrugRisk cautions that patients should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*JPML 5/15/13; jpml.uscourts.gov/sites/jpml/files/Pending%20MDL%20Dockets_By%20District_May-14-2013.pdf

**BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398

***FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf

****Bayer 2/28/13; annualreport2012.bayer.com/en/legal-risks.aspx

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebyasmin-side-effects/litigation-news/prweb10765550.htm


Source: prweb



comments powered by Disqus